BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis. METHODS: A phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY-520 given as a 1-hour infusion in either a single dose or on a day 1, 3, and 5 divided-dose schedule per cycle in patients with advanced or refractory myeloid leukemias. Additional objectives were to characterize pharmacokinetics, assess preliminary clinical activity, and explore biomarkers of KSP inhibition with ARRY-520. A total of 36 patients with acute myelogenous leukemia (n = 34) or myelodysplastic syndromes (n = 2) with a median age of 66 years (range, 21-88 years) were enrolled: 15 in the single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2)) and 21 in the divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day). RESULTS: The MTD was 4.5 mg/m(2) total dose per cycle for both dose schedules. Dose-limiting toxicities included mucositis, exfoliative rash, hand-foot syndrome, and hyperbilirubinemia. Grades 3 or 4 reversible drug-related myelosuppression were observed in 33 of 36 patients. Plasma pharmacokinetic analyses revealed low clearance of ARRY-520 (~3 L/hour), a volume of distribution of ~450 L, and a median terminal half-life of >90 hours. Monopolar spindles were observed in blood mononuclear cells, through use of 4',6-diamidino-2-phenylindole nucleic acid stain and antitubulin antibodies. CONCLUSIONS: On the basis of the relative lack of clinical activity, further development of ARRY-520 as an antileukemic agent was halted. (Clinicaltrials.gov identifier NCT00637052).
BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis. METHODS: A phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY-520 given as a 1-hour infusion in either a single dose or on a day 1, 3, and 5 divided-dose schedule per cycle in patients with advanced or refractory myeloid leukemias. Additional objectives were to characterize pharmacokinetics, assess preliminary clinical activity, and explore biomarkers of KSP inhibition with ARRY-520. A total of 36 patients with acute myelogenous leukemia (n = 34) or myelodysplastic syndromes (n = 2) with a median age of 66 years (range, 21-88 years) were enrolled: 15 in the single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2)) and 21 in the divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day). RESULTS: The MTD was 4.5 mg/m(2) total dose per cycle for both dose schedules. Dose-limiting toxicities included mucositis, exfoliative rash, hand-foot syndrome, and hyperbilirubinemia. Grades 3 or 4 reversible drug-related myelosuppression were observed in 33 of 36 patients. Plasma pharmacokinetic analyses revealed low clearance of ARRY-520 (~3 L/hour), a volume of distribution of ~450 L, and a median terminal half-life of >90 hours. Monopolar spindles were observed in blood mononuclear cells, through use of 4',6-diamidino-2-phenylindole nucleic acid stain and antitubulin antibodies. CONCLUSIONS: On the basis of the relative lack of clinical activity, further development of ARRY-520 as an antileukemic agent was halted. (Clinicaltrials.gov identifier NCT00637052).
Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian Journal: Blood Date: 2006-04-11 Impact factor: 22.113
Authors: P A Cassileth; D P Harrington; F R Appelbaum; H M Lazarus; J M Rowe; E Paietta; C Willman; D D Hurd; J M Bennett; K G Blume; D R Head; P H Wiernik Journal: N Engl J Med Date: 1998-12-03 Impact factor: 91.245
Authors: H D Preisler; Y Rustum; E S Henderson; S Bjornsson; P J Creaven; D J Higby; A Freeman; S Gailani; C Naeher Journal: Blood Date: 1979-03 Impact factor: 22.113
Authors: P H Wiernik; P L Banks; D C Case; Z A Arlin; P O Periman; M B Todd; P S Ritch; R E Enck; A B Weitberg Journal: Blood Date: 1992-01-15 Impact factor: 22.113
Authors: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim Journal: Gene Date: 2013-08-14 Impact factor: 3.688
Authors: Monica Venere; Craig Horbinski; James F Crish; Xun Jin; Amit Vasanji; Jennifer Major; Amy C Burrows; Cathleen Chang; John Prokop; Quilian Wu; Peter A Sims; Peter Canoll; Matthew K Summers; Steven S Rosenfeld; Jeremy N Rich Journal: Sci Transl Med Date: 2015-09-09 Impact factor: 17.956
Authors: A Hollebecque; E Deutsch; C Massard; C Gomez-Roca; R Bahleda; V Ribrag; C Bourgier; V Lazar; L Lacroix; A Gazzah; A Varga; T de Baere; F Beier; S Kroesser; K Trang; F T Zenke; M Klevesath; Jean-Charles Soria Journal: Invest New Drugs Date: 2013-12 Impact factor: 3.850
Authors: Omar S Aljitawi; Dandan Li; Yinghua Xiao; Da Zhang; Karthik Ramachandran; Lisa Stehno-Bittel; Peter Van Veldhuizen; Tara L Lin; Suman Kambhampati; Rama Garimella Journal: Leuk Lymphoma Date: 2013-05-15